10-Q: NextCure Faces Going Concern Doubt Amidst Avere Merger Uncertainty

NextCure, Inc. reported substantial net losses and cash burn, raising going concern doubts, while progressing towards a proposed merger with Avere Therapeutics, Inc.

Summary

• NextCure, Inc. filed its quarterly report for the period ended September 30, 2026, highlighting significant financial challenges and strategic shifts.
• The company reported a net loss of $6.8 million for the three months ended September 30, 2026, and $31.5 million for the nine months ended September 30, 2026.
• Cash and cash equivalents stood at $8.7 million as of September 30, 2026, with management estimating these funds will only support operations into early 2027, raising substantial doubt about the company's ability to continue as a going concern.
• The company is actively pursuing a proposed merger with Avere Therapeutics, Inc., expected to close in Q4 2026, which is contingent on stockholder approval and other closing conditions.
• Significant restructuring activities, including workforce reductions and facility lease terminations, were undertaken to align operations with anticipated needs pending the merger.
• Development activities for SIM0505 and LNCB74 have been largely discontinued or transitioned to other parties.
• The company is focused on supporting existing collaboration obligations, managing legacy assets, and completing the proposed merger.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the company's going concern issues, significant net losses, and the uncertainty surrounding the proposed merger, despite ongoing restructuring efforts.

Positives

• The company has significantly reduced its operating cash requirements through restructuring activities.
• The proposed merger with Avere Therapeutics, Inc. is progressing, with a registration statement declared effective and a stockholder meeting scheduled.
• Avere has secured substantial private financing commitments ($820.0 million) contingent upon the merger closing.
• The company successfully completed the transfer of the LNCB74 IND and regulatory responsibilities to LigaChem.
• The Delaware Court of Chancery validated the company's July 2025 reverse stock split amendment and all shares issued in reliance thereon.

Negatives

• The company has an accumulated deficit of $468 million as of September 30, 2026.
• Cash and cash equivalents of $8.7 million are projected to fund operations only into early 2027, raising substantial doubt about the ability to continue as a going concern.
• The company incurred a net loss of $6.8 million for the three months and $31.5 million for the nine months ended September 30, 2026.
• Research and development expenses decreased significantly due to wind-down of activities, but general and administrative expenses increased due to merger-related professional fees.
• The proposed merger is subject to numerous closing conditions, including stockholder approval, and there is uncertainty regarding its completion.
• If the merger is not completed, the company may need to seek additional funding, pursue asset sales, or consider dissolution and liquidation, with a high likelihood of stockholders losing their investment.

Risks

• The proposed merger with Avere may not be completed on the contemplated terms or within the expected timeframe, or at all, which could adversely affect the business, financial condition, and results of operations.
• The company's common stock equity is below Nasdaq's minimum requirement, posing a risk to its listing status.
• The private placement financing to be completed concurrently with the merger may not be completed on the contemplated terms or at all, potentially impacting the merger's feasibility.
• Even if the merger is completed, the combined company may incur losses for the foreseeable future and might never achieve or sustain profitability.
• Stockholders may not receive any payment on the Contingent Value Rights (CVRs), and the CVRs may expire valueless.
• The company's ability to utilize its net operating loss carryforwards and tax credits may be substantially limited following the proposed merger due to Sections 382 and 383 of the IRC.

Future Outlook

The company expects its existing cash and cash equivalents to fund operations into early 2027, but this is contingent on the completion of the proposed merger with Avere and continued restructuring efforts. Future expenditures will focus on supporting obligations, managing legacy assets, and merger-related activities. Significant future operating losses are anticipated.

Management Comments

• Management believes its cash and cash equivalents will only be sufficient to fund the Company's operations into early 2027.
• The Company will require additional funding to sustain operations beyond that period and expects to continue generating operating losses for the foreseeable future.
• Management's plans to alleviate conditions that raise substantial doubt include completing the proposed Merger with Avere, continuing to implement restructuring activities, and pursuing partnership, licensing, sale and other opportunities.
• The Company's future operations are highly dependent on the closing of the Merger and there can be no assurances that the Merger will be successfully consummated.
• If the Merger is not consummated, the Company believes that its cash and cash equivalents as of September 30, 2026 would be adequate to fund its operating expenses into early 2027. However, in order to continue operations and execute its strategic plan, the Company would need to secure substantial additional funding in the future.

Industry Context

StockSavvy.ai notes that NextCure's situation reflects a common challenge in the biopharmaceutical industry where companies often face significant cash burn and rely on strategic transactions like mergers or financings to sustain operations and advance drug development. The shift in focus from oncology to inflammatory diseases via the Avere merger highlights the dynamic nature of therapeutic area development and corporate strategy in the sector.

Comparison to Industry Standards

• The company's net loss of $31.5 million for nine months is substantial, but within the range of early-stage biopharmaceutical companies that are pre-revenue and investing heavily in R&D.
• The cash runway extending into early 2027 with $8.7 million in cash is concerning, as many companies in this sector aim for a longer runway (18-24 months) to de-risk development and financing activities.
• The significant restructuring and workforce reduction align with industry practices when facing financial distress or undergoing major strategic shifts like mergers.
• The reliance on a merger for future funding is a common, albeit high-risk, strategy for companies facing going concern issues, as seen in numerous biotech transactions.

Management Changes

Legal Proceedings

• The company filed a petition in the Delaware Court of Chancery seeking validation of its July 2025 reverse stock split amendment and all shares issued in reliance thereon. This matter was resolved on November 2, 2026, with the court granting the requested relief.

Stakeholder Impact

• Shareholders face significant uncertainty regarding the completion of the merger and the potential value of their investment, with a high likelihood of losing their investment if the merger fails and the company liquidates.
• Contingent Value Rights (CVRs) will be issued to pre-merger NextCure stockholders, tied to the future monetization of legacy assets, with no guarantee of payment.
• Employees have been significantly impacted by restructuring and workforce reductions.
• Creditors and suppliers may face uncertainty regarding payment if the company's going concern status is not resolved.
• Collaborators like LigaChem and Zaiming are impacted by the strategic shifts, with LNCB74 transitioned to LigaChem and SIM0505 development winding down.

Next Steps

• Complete the proposed merger with Avere Therapeutics, Inc.
• Obtain stockholder approval for the proposed merger.
• Continue to support ongoing obligations under existing collaboration and license agreements.
• Evaluate strategic alternatives for legacy assets and intellectual property.
• Conduct study close-out activities for the SIM0505 program.
• Complete restructuring-related payments, expected by Q4 2026.
• Address Nasdaq listing compliance requirements.

Key Dates

Recommendation

The company is in a highly transitional phase with significant going concern risks. While the proposed merger with Avere offers a potential path forward and access to substantial capital, its completion is uncertain. The current financial situation and the uncertainty surrounding the merger warrant a 'hold' recommendation, as the outcome is heavily dependent on external factors and stockholder approval. Investors should monitor the merger progress and Avere's financing closely.

Keywords

biopharmaceutical, merger, restructuring, going concern, clinical trials, asset monetization, net loss, cash runway